Victoria Socha

DocwireNews

In patients with autosomal dominant polycystic kidney disease (ADPKD), the progressive nature of declining kidney function is associated with increased risk of cardiovascular events and mortality. Patrick Gagnon-Sanschagrin, BSc, and colleagues recently conducted an analysis to examine the use of healthcare resources and costs associated with increasing renal dysfunction in patients with ADPKD. Results were reported online at the NKF Spring Clinical Meetings. The report was titled Substantial Excess Healthcare Costs in Commercial and Medicare Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) with Advanced Renal Dysfunction.The researchers utilized IBM MarketScan&reg; Commercial and Medicare Advantage Supplemental Databases from January 1, 2015, to December 31, 2107, to conduct a retrospective matched cohort claims analysis. Patients with ADPKD were eligible for the analysis if they had continuous enrollment and two International Classification of Diseases, Tenth Edition, Clinical Modification diagnosis codes for ADPKD.Each patient with ADPKD was matched with up to three different patients without ADPKD (controls) by age, sex, region of residence, insurance plan, and calendar year. Differences in costs per patient per year (PPPY) between cohorts were estimated using index renal function stage.The analysis included 7861 eligible patients with ADPKD and 22,928 controls in the commercial cohorts and 1366 eligible patients with ADPKD and 3922 controls in the Medicare Advantage cohorts. Costs in the ADPKD cohorts were higher than in the control cohorts.There were significant variations in costs by index renal function stage. Total cost differences incurred among patients receiving dialysis were 34 to 37 times greater compared with patients with CKD stage 1 (commercial: $205,073 PPPY vs $6024 PPPY; Medicare: $259,974 PPPY vs $6984 PPPY).In conclusion, the researchers said, &ldquo;This study supports previous estimates of the excess economic burden among patients with ADPKD. Compared with controls, patients with ADPKD incur higher costs in both commercial and Medicare plans and the costs increase with renal impairment. Interventions to prevent loss of renal function early in the disease process have the potential to reduce substantial healthcare charges.&rdquo;Source: Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, Cloutier M. Substantial excess healthcare costs in commercial and Medicare patients with autosomal dominant polycystic kidney disease (ADPKD) with advanced renal dysfunction. Abstract of a presentation at the National Kidney Foundation 2020 Spring Clinical Meetings; abstract #378.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Healthcare Costs Higher in Patients with ADPKD and Advanced Renal Dysfunction

National Kidney Foundation 2020

In patients with autosomal dominant polycystic kidney disease (ADPKD), the progressive nature of declining kidney function is associated with increased risk of cardiovascular ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe